Fiduciary Alliance LLC Increases Holdings in Eli Lilly and Company $LLY

Fiduciary Alliance LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 5.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,807 shares of the company’s stock after buying an additional 536 shares during the quarter. Fiduciary Alliance LLC’s holdings in Eli Lilly and Company were worth $9,781,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in LLY. Kestra Private Wealth Services LLC increased its holdings in Eli Lilly and Company by 5.4% in the 1st quarter. Kestra Private Wealth Services LLC now owns 54,306 shares of the company’s stock worth $49,949,000 after acquiring an additional 2,781 shares in the last quarter. Chatterton & Associates Inc. boosted its stake in shares of Eli Lilly and Company by 14.1% in the first quarter. Chatterton & Associates Inc. now owns 557 shares of the company’s stock worth $532,000 after acquiring an additional 69 shares during the period. Arta Finance Wealth Management LLC raised its stake in Eli Lilly and Company by 4.4% during the 1st quarter. Arta Finance Wealth Management LLC now owns 405 shares of the company’s stock valued at $373,000 after purchasing an additional 17 shares during the period. 25 LLC lifted its holdings in Eli Lilly and Company by 13.6% in the 1st quarter. 25 LLC now owns 526 shares of the company’s stock worth $484,000 after purchasing an additional 63 shares in the last quarter. Finally, Cardinal Point Capital Management ULC boosted its stake in Eli Lilly and Company by 43.4% in the 1st quarter. Cardinal Point Capital Management ULC now owns 941 shares of the company’s stock worth $865,000 after purchasing an additional 285 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. Barclays raised their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price target for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,235.07.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,206.51 on Friday. The firm has a fifty day simple moving average of $1,036.28 and a two-hundred day simple moving average of $1,020.95. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,215.76. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $1.14 trillion, a P/E ratio of 42.86, a PEG ratio of 1.23 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the company earned $3.34 EPS. The business’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.